Michael Ploug
Ph.d., DSc.
Telephone: +45 3545 6037
Email: m-ploug(at)finsenlab.dk
Michael Ploug's personal site
Group Leader
Ploug Group
Key research interests
The research of this group is predominantly focused on structural and functional aspects of proteins involved in invasion, metastasis and matrix degradation in human cancer.
The cellular receptor for the urokinase-type plasminogen activator (uPAR) and its structural homologues C4.4A and Haldisin are presently being the primary components under study.
The ultimate goal of these studies is to elucidate the function of these proteins in vitro and in vivo and to develop intervention strategies that can be applied under certain pathological conditions including methods of non-invasive biomolecular imaging using positron emission tomography (PET).
Workflow for our studies is illustrated below for our research on uPAR:
_.jpg)
Kriegbaum et al. : “Rational targeting of the urokinase receptor (uPAR):
Development of antagonists and non - invasive imaging probes”. Current Drug Targets. 2011; in press.
Development of antagonists and non - invasive imaging probes”. Current Drug Targets. 2011; in press.
